



In vitro screening on β -amyloid peptide production of plants used in traditional medicine for cognitive disorders

Salim Hage^{a,*}, Pascal Kienlen-Campard^b, Jean-Noël Octave^b, Joëlle Quetin-Leclercq^a

^a Pharmacognosy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (U.C.L.), Avenue E. Mounier 72-30, B-1200 Brussels (Woluwe-Saint-Lambert), Belgium

^b Institute of Neuroscience (IoNS), Université catholique de Louvain (U.C.L.), Avenue Hippocrate 54, B-1200 Brussels (Woluwe-Saint-Lambert), Belgium

ARTICLE INFO

Article history:

Received 7 May 2010

Received in revised form 16 July 2010

Accepted 20 July 2010

Available online 29 July 2010

Keywords:

Alzheimer's disease
 β -Amyloid peptide
 Traditional medicine
 Benin
 Pharmacognosy
Centella asiatica
Cissampelos owariensis
Heteranthera callifolia
Oldenlandia affinis
Parkia biglobosa
Prosopis africana
Pterocarpus erinaceus
Rauwolfia vomitoria
Trichilia emetica

ABSTRACT

Aim of the study: The aim of the study was to investigate the activity on β -amyloid peptide production of crude extracts of 9 plant species traditionally used in Benin or in Madagascar for the treatment of cognitive disorders, in order to select candidates for Alzheimer's disease treatment.

Materials and methods: For each species, hexane, dichloromethane, ethyl-acetate and water extracts were tested, at non-toxic concentrations, on CHO cells overexpressing the human neuronal β -amyloid peptide precursor (APP695) to measure variations of APP processing (by Western-blotting) and, for the most active, of A β -amyloid production (by ECLIA).

Results: We observed, at non-toxic concentrations, a significant increase in CTF/APP ratio with *Oldenlandia affinis* cyclotide-enriched fraction, *Prosopis africana* EtOAc extract, *Pterocarpus erinaceus* aqueous extract and *Trichilia emetica* hexane extract. We also showed that the *Pterocarpus erinaceus* extract significantly decreased A β production, displaying effects similar to those of DAPT (γ -secretase inhibitor) on APP processing, but may act on another inhibition site.

Conclusion: These active extracts are worth further studies to isolate the compounds responsible for the observed activities, to analyze their mode of action and determine their clinical potentials.

© 2010 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Alzheimer's disease is the most widespread cause of age-linked dementia. This incurable dementia is histologically diagnosed by the presence, especially in hippocampus and cortex, of both intraneuronal hyperphosphorylated tau protein tangles and extra-neuronal senile plaques; these plaques are mainly constituted by aggregated β -amyloid peptide (A β) (Annaert and de Strooper, 2002; Kienlen-Campard and Octave, 2002).

This peptide, in addition to forming plaques, which cause oxidative stress in the neighbouring neurons and synapse disorders, causes a neurotoxic effect by its intraneuronal accumulation and by forming soluble oligomers (Suh and Checler, 2002).

The metabolic pathways involved in A β production have been thoroughly studied in the last two decades (Suh and Checler, 2002). Briefly, the β -amyloid precursor protein (APP) is a type I trans-membrane protein processed by two catabolic pathways: in the non-amyloidogenic pathway, APP is cleaved by an α -secretase activity generating a soluble α -APP and an α C-terminal fragment (α -CTF) anchored in the membrane; in the amyloidogenic pathway, APP is cleaved by the APP-cleaving enzyme (BACE) generating a soluble β -APP and a transmembrane β -C-terminal fragment (β -CTF); both α - and β -CTFs are substrates of a γ -secretase activity which releases P3 and A β , respectively, with the concomitant production of APP intracellular domain (AICD).

Several studies with promising results have been made on plant species traditionally used against memory disorders, especially in Indian and Chinese traditional medicine (e.g., Howes and Houghton, 2003); the most known and used being the *Ginkgo*

Abbreviations: ATCC, American type culture collection; BSA, Bovine serum albumine; DAPT, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; DMSO, dimethylsulfoxide; FBS, foetal bovine serum; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide or thiazol blue tetrazolium bromide; PAF, platelet-activating factor; PS, presenilin; TPA, Trypopylamine.

* Corresponding author. Tel.: +32 2 764 72 34; fax: +32 2 764 72 53.

E-mail addresses: Salim.Hage@uclouvain.be, sa_hage@hotmail.com (S. Hage), Pascal.Kienlen-Campard@uclouvain.be (P. Kienlen-Campard), Jean-Noel.Octave@uclouvain.be (J.-N. Octave), Joelle.Leclercq@uclouvain.be (J. Quetin-Leclercq).

Table 1
Studied plant species.

Botanical name	Part studied ^a	Family	Place and date of collection	Voucher number
<i>Centella asiatica</i> (L.) Urban	LF	Apiaceae	Mangoro, sept. 2007	2007sept. Mangoro
<i>Cissampelos owariensis</i> P. Beauvais ex D.C.	AP	Menispermaceae	Azowtisse, oct. 2007	AA 6348/HNB
<i>Heteranthera callifolia</i> Rchb. ex Kunth	WP	Pontederiaceae	Dangbo, oct. 2007	AA 6349/HNB
<i>Oldenlandia affinis</i> (R. et S.) D.C.	AP/WP	Rubiaceae	Abomey-Calavi, oct. 2007	AA 6350/HNB
<i>Parkia biglobosa</i> (Jacq.) R.Br. ex G. Don f.	TW	Fabaceae	Benin, oct. 2007	AA 6351/HNB
<i>Prosopis africana</i> (Guill. & Perr.) Taub	HW	Fabaceae	Benin, oct. 2007	AA 6353/HNB
<i>Pterocarpus erinaceus</i> Poiret	SB	Fabaceae	Benin, oct. 2007	AA 6355/HNB
<i>Rauwolfia vomitoria</i> Afzelius	LF	Apocynaceae	Azowtisse, 16 oct. 2007	AA 6356/HNB
<i>Trichilia emetica</i> Vahl. suberosa J.J.F.E. De Wilde	LF	Meliaceae	Benin, oct. 2007	AA 6357/HNB

^a Plant part used: AP, aerial parts; LF, leaves; SB, stem bark; SHW, stem and bough heart-wood; TW, twigs; WP, whole plant.

biloba L. (Ginkgoaceae) extract EGb761, which has shown cognitive improvement in animals and humans, likely because of a synergy between various compounds: its flavonoids are antioxidant and vasodilatory, and rescue neurons from toxicity induced by A β or H₂O₂, ginkgolide A inhibits A β oligomerization, ginkgolide B inhibits PAF and thus interferes with inflammatory processes. The extract has also been shown to increase choline uptake and synaptic plasticity in hippocampus (Bastianetto et al., 2000; De Feudis and Drieu, 2000; Yao et al., 2001; Howes and Houghton, 2003; Wu et al., 2006).

We selected a series of plants traditionally used for memory problems by traditional practitioners in Benin or Madagascar, and which had never been studied for Alzheimer's disease (except *Centella asiatica*). As popular medicine does not know Alzheimer's disease as such, we chose plants according to Alzheimer-related symptoms: some were indicated for «memory loss», others for «madness», and others for «learning retardation» (Adjanohoun et al., 1989). Nine plants were finally selected. From each species we prepared successive extracts in Soxhlet apparatus by hexane, dichloromethane, ethyl-acetate and water. Crude extracts were evaluated for their action upon APP catabolism and in particular A β production.

2. Materials and methods

2.1. Chemicals, reagents and materials

Analytical grade solvents were obtained: ethyl-acetate and *n*-hexane from Sigma–Aldrich Chemie GmbH (Steinheim, Germany); dichloromethane from Fluka (Buchs, Switzerland); ultra-pure water in MilliPore (Bedford, USA) columns, and ethanol and methanol by redistillation.

Cellulose extraction thimbles (MN645) and polyamide SC6 (MN815620) were purchased from Macherey–Nagel GmbH & Co. KG (Düren, Germany); DMSO and MTT from Sigma–Aldrich; Ham-F12 medium, fungizone (amphotericin B) and Nu-Page 4–12% bis-tris gels from Invitrogen (Paisley, UK, and Carlsbad, CA); penicillin-streptomycin solution and G418 from BioWhittaker (Lonza, Walkersville, USA). DAPT was a generous gift from Luc Mercken, Aventis, Paris. *Ginkgo biloba* standardized extract (EGb 761) was a kind gift of Dr. Willmar Schwabe GmbH & Co. KG (Kalsruhe, Germany).

The human specific anti-APP WO-2 antibody was obtained from The Genetics Company (Schlieren, Switzerland). The anti-APP C-terminal antibody was kindly provided by N. Sergeant (INSERM U422, Lille, France). Secondary antibodies were from Amersham Bioscience (Uppsala, Sweden). ECL revelation was performed with the *Western Lightning Chemiluminescence Reagent Plus* kit of Perkin Elmer Inc. (Waltham, Massachusetts, USA).

2.2. Plant materials

Beninese plants were chosen in the ethnopharmacological exploratory book of Adjanohoun et al. (1989), with indications as memory loss, learning retardation, and madness as described in the introduction. They were collected and identified by Dr. Pierre Agbani, vouchers were deposited at the Herbar National of Abomey-Calavi University (Bénin).

Centella asiatica leaves were chosen due to their current popular use in India (already mentioned for memory in Ayurvedic medicine) and Madagascar against Alzheimer's disease and as memory improver (Howes and Houghton, 2003; Zheng and Qin, 2007), and were collected for us in Mangoro (East of Madagascar) in sept. 2007, and voucher specimens were deposited at the *Institut Malgache des Recherches Appliquées* (Antananarivo, Madagascar).

Plant names, families, organs, origins, collecting dates and voucher specimen numbers are given in Table 1.

2.3. Preparation of extracts

Plant materials were dried at room temperature, and then pulverised using a blender and sieved (365 μ m, but 710 μ m for *Parkia biglobosa* twigs because of their hardness). However, *Pterocarpus erinaceus* bark and *Prosopis africana* heart-wood were cut with a rabbit hand-plane before powdering. 9–12 g powder of each plant was extracted (Soxhlet apparatus) successively by 250 ml of *n*-hexane, dichloromethane (or chloroform), ethyl-acetate, milli-Q water.

For *Centella asiatica*, a supplementary extraction was made according to the *European Pharmacopoeia* (2008): 8 h of Soxhlet extraction by methanol.

For *Oldenlandia affinis*, we also made a cyclotide-enriched extract: after maceration of 12 g plant powder 16 h in 280 ml of water:MeOH (1:1) under agitation and elimination of MeOH by vacuum, the aqueous solution was washed by 3 times 250 ml of CH₂Cl₂; the aqueous fraction contains cyclotides, as mentioned by Herrmann et al. (2008), while the CH₂Cl₂ fraction was also concentrated and tested.

Organic solvents were eliminated by evaporation under vacuum; water was eliminated by lyophilization. The yields are given in Table 2. For the following tests, unless otherwise mentioned, extracts were dissolved at 20 mg/ml in DMSO for organic extracts, in water: ethanol 2:1 for aqueous extracts; the exceptions are *Centella asiatica* MeOH, and *Pterocarpus erinaceus* hexane dissolved in DMSO: EtOH: water 3:1:2, and *Heteranthera callifolia* CH₂Cl₂ dissolved in DMSO: EtOH: water 3:2:1.

2.4. Cytotoxicity tests

We used CHO-K1 cells (from ATCC, line CCL-61, batch 4765275), cultivated in Ham-F12 medium supplemented with FBS (10%),

Table 2

Yields, cytotoxicity results, chosen concentrations and CTF/APP ratios of all selected plant extracts and reference compounds.

Plant species or substance	Extract	Yield ^a (%)	Cytotoxicity on CHO cells		Chosen conc. ^b (μg/ml)	CTF/APP ratio ^c	
			IC ₅₀ (μg/ml), averages	Confidence intervals			
<i>Centella asiatica</i>	Hexane	1.53	70.2	64.9; 75.9	25	1.0	±0.1
	CH ₂ Cl ₂	0.84	76.0	71.1; 81.2	25	0.7	±0.2
	EtOAc	2.01	156.3	152.3; 160.4	100	0.9	±0.1
	Water	23.97	>200	/	200	0.7	±0.1
	MeOH (Ph. Eur.)	25.01	>200	/	50	1.1	±0.4
<i>Cissampelos owariensis</i>	Hexane	2.93	122.4	115.0; 130.2	50	0.0	±0.001
	CH ₂ Cl ₂	1.18	20.5	19.7; 21.4	6.25	0.5	±0.1
	EtOAc	1.38	>200	/	100	0.2	±0.03
	Water	6.85	>200	/	200	0.9	±0.1
<i>Heteranthera callifolia</i>	Hexane	0.56	31.6	30.8; 32.5	6.25	0.6	±0.1
	CH ₂ Cl ₂	0.44	157.9	140.4; 177.6	100	1.1	±0.3
	EtOAc	0.46	199.1	170.4; 232.6	25	0.4	±0.03
	Water	9.39	>200	/	200	0.6	±0.1
<i>Oldenlandia affinis</i>	Hexane	1.95	51.6	50.1; 53.5	12.5	0.5	±0.1
	CH ₂ Cl ₂	1.66	10.4	10.1; 10.6	6.25	0.4	±0.07
	EtOAc	0.71	>200	/	100	0.7	±0.1
	Water	4.25	80.9	79.6; 82.1	50	1.1	±0.2
	Cyclotide-enriched fraction	15.12	72.2	67.8; 77.0	50	2.1	±0.7**
	CH ₂ Cl ₂ fraction	0.65	35.1	33.6; 36.6	25	0.7	±0.07
<i>Parkia biglobosa</i>	Hexane	5.21	33.2	32.3; 34.1	12.5	1.1	±0.3
	CH ₂ Cl ₂	0.64	36.3	35.2; 37.5	12.5	1.0	±0.8
	EtOAc	2.98	>200	/	200	1.3	±0.3
	Water	3.79	>200	/	200	0.6	±0.1
<i>Prosopis africana</i>	Hexane	0.27	73.2	68.1; 78.7	25	0.8	±0.1
	CH ₂ Cl ₂	0.06	124.8	111.4; 139.9	25	1.0	±0.2
	EtOAc	1.06	187.4	177.1; 198.3	100	2.2	±0.6**
	Water	2.70	>200	/	200	0.6	±0.4
<i>Pterocarpus erinaceus</i>	Hexane	0.48	18.5	17.3; 19.7	6.25	1.2	±0.4
	CH ₂ Cl ₂	0.18	12.5	11.1; 14.2	6.25	0.7	±0.07
	EtOAc	0.26	99.8	90.8; 109.7	12.5	0.5	±0.1
	Water	22.00	262.1	244.5; 281.0	200	7.4	±3.2**
					100	5.2	±2.8**
<i>Rauwolfia vomitoria</i>	Water tannins removed	75.73	>200	/	100	2.1	±0.5**
	Hexane	4.60	>200	/	50	0.2	±0.01
	CH ₂ Cl ₂	1.40	28.0	27.8; 28.3	12.5	1.0	±0.1
	EtOAc	1.98	132.7	128.9; 136.5	25	0.20	±0.04
	Water	6.17	>200	/	200	0.6	±0.2
<i>Trichilia emetica suberosa</i>	Hexane	6.22	>200	/	100	1.5	±0.4*
	CHCl ₃	1.37	124.8	120.8; 129.0	25	0.7	±0.08
	EtOAc	0.73	204.2	193.1; 216.0	50	1.1	±0.1
	Water	12.14	>200	/	200	1.2	±0.4
Non-treated CHO-APP cells						1	±0.2
CHO-APP cells without G418						0.8	±0.1
Cycloheximide			0.41	0.35; 0.48	/	/	/
EGb 761 (Ginkgo)			>200	/	200	1.0	±0.1
DAPT			n.d.	n.d.	0.108 (i.e. 250 nM)	8.3	±3.9**

^a Yields are calculated according to the weight of plant powder, excepted for the *Pterocarpus erinaceus* tannin-free aqueous fraction, for which it was calculated according to the weight of crude aqueous extract.

^b Chosen concentrations provide at least 80% of viability after 72 h treatment.

^c CTF/APP ratios significantly superior to control cells are indicated by **($p < 0.01$ with Student's *t*-test) or by *($p < 0.05$) ($n = 3$).

Penicillin-Streptomycin (ana 100 UI/ml) and Amphotericin B (2.6 μg/ml). Cells were treated and MTT colorimetric assay was performed as previously described by Block et al. (2002). In brief, cells were counted and seeded in 96-well plates (10,000 cells per well in 100 μl of medium); one day after, medium was removed and replaced by 200 μl fresh medium containing the extracts at various concentrations. Each plate contained control wells (non-treated cells); cycloheximide treatments were used as reference cytotoxic conditions and toxicity of the solvents was assayed at their maximal tested concentrations.

72 h after treatment, medium was removed and replaced by 100 μl of a 0.03% MTT solution in culture medium without FBS for 45 min at room temperature; then, MTT solution was removed and replaced by 100 μl DMSO. Absorbance was read at 570 and 620 nm, using a SpectraMax 190 spectrophotometer (Molecular Devices, Sunnyvale, CA, USA) with the Soft Max Pro program.

Data were analyzed on Graph Pad Prism 4.0, by non-linear regression to determine the IC₅₀. Non-toxic concentrations were determined individually as maintaining at least 80% of viability.

2.5. Cell line for activity screening tests

We used CHO cells stably expressing human APP695 protein (Essalmani et al., 1996). These CHO-APP cells were cultivated as described by Octave et al. (2000), in Ham-F12 medium supplemented with FBS (10%), Penicillin-Streptomycin (ana 100 UI/ml) and with G418 as selection agent (250 μg/ml).

Cells were seeded in 6-well plates (300,000 cells/well). One day after, we treated them by replacing their medium with new medium containing our extract solutions at the maximal non-toxic concentration, or DAPT at 250 nM (0.108 μg/ml), or EGb761 at 200 μg/ml. Sixteen hours after treatment, extracel-




Fig. 1. Western-blot bands of CHO cells expressing APP, treated with DAPT or *Pterocarpus erinaceus* aqueous extract. Cell-lysates of CHO cells expressing human APP695 were analyzed by Western-blotting with the C-ter antibody, directed against the 17 C-terminal residues of APP. Cells were treated for 16 h with *Pterocarpus erinaceus* extracts at indicated concentrations or with 250 nM DAPT, a functional γ -secretase inhibitor. The expected positions of full-length APP (APP), α - and β -cleaved C-terminal fragments (α -CTF and β -CTF) and soluble APP Intracellular C-terminal Domain (AICD) are indicated.

lular media were pipetted and frozen for A β measurements, whereas cells were scraped in PBS and recovered by centrifugation (28,000 $\times$ g).

Protein analysis by Western-blotting (10% SDS-PAGE) was realized as previously described by Huyseynne et al. (2007). In brief, cells were lysed by 4 s sonication in Laemmli lysis buffer and were loaded (5 μ g of protein) onto 10–20% bis-tris gels, and blotted onto nitrocellulose membranes; membranes were then saturated (5% skimmed milk in 0.05% Tween 20/PBS) for 30 min, washed, incubated overnight at 4°C with the primary antibody (diluted in 0.05% Tween 20/PBS) at the following concentrations: 0.5 μ g/ml for the human APP-specific WO-2 antibody and 1:5000 for the anti-APP C-terminal antibody. Membranes were then washed and incubated with horseradish peroxidase-conjugated secondary antibody (1/10,000 of the anti-mouse sheep IgG when primary antibody was WO-2, 1/15,000 of the anti-rabbit donkey IgG when primary antibody was anti-C-terminal). After washing, the immunoreactive bands were visualized by chemiluminescence (ECL revelation). Signals were quantified using the Quantity One software coupled to the Gel Doc 2000 device (Bio-Rad, Hercules, CA).

2.6. A β measurements

In extracellular media of treated or non-treated cells, we measured the concentration of three species of β -amyloid peptide: A β 38, A β 40, A β 42, by Electro-Chemiluminescence Immuno-Assay (ECLIA). Its principle was described by Best et al. (2005), and the assays were performed according to the manufacturer's instructions. Briefly, samples were analyzed using Meso Scale Discovery (MSD) SECTORTM Imager 2400 (Meso Scale Discovery, Gaithersburg, MD, USA), with the Human A β triplex kit (also from MSD); carbene 96-well plates contained in each well four capture spots, one of which is blocked with BSA (as standard curve control), and the three others coated with isoform specific anti-A β antibodies specific for A β 38, A β 40, A β 42, respectively. 100 μ l of blocking buffer solution were added to all wells to avoid non-specific binding. The plates were then sealed, wrapped in tin foil, and incubated at room temperature on a plate shaker (600 rpm) for 1 h. At the end of the incubation, the wells were washed three times with washing buffer, and 25 μ l of the standards (A β 38, A β 40, A β 42) and samples were then added to the wells, followed by an A β -detecting antibody at 1 μ g/ml (MSD) labelled with a Ruthenium (II) trisbipyridine N-hydroxysuccinimide ester; this detection antibody is either 4G8 (which recognizes the epitope A β 18–22 of the human and rodent peptide) or 6E10 (recognizing specifically amino-acids

3–8 of human A β). Plates were then aspirated and washed 3 times; MSD read buffer (containing TPA) was added to wells before reading on the Sector Imager; a small electric current through the micro-electrodes present in each well produces a redox reaction of the Ru²⁺ cation, with emission of a measured 620 nm red light ray. Using dose–response curves, we calculated for each sample the concentration of each A β isoform, the blank being cell-less culture medium.

2.7. Elimination of tannins

Pterocarpus erinaceus aqueous extract was impoverished in tannins by retention of these compounds on polyamide column, as described by Houghton and Raman (1998).

2.8. Statistical analysis

The number of samples (n) under each experimental condition is indicated in the legends of tables or figures. When two experimental conditions were compared, statistical analysis was performed via unpaired t -test. Otherwise, statistical analysis was performed by one-way analysis of variance (ANOVA), followed by Dunnett's multiple-comparisons post-test (Prism 4.0, GraphPad Software Inc., San Diego, CA).

3. Results

3.1. Cytotoxicity tests

The 39 extracts prepared as described in Section 2 (yields are given in Table 2) were tested on CHO cells for their potential cytotoxicity, to exclude that our further results on A β production were due to toxicity. We tested each extract during 72 h at least at six different concentrations in at least 12 wells; we determined for each extract the IC₅₀, the concentration at which 50% of mortality is observed, and the to-be-used concentration as the highest concentration tested with more than 80% viability. Results are given in Table 2.

The results obtained with the reference cytotoxic compound (cycloheximide) and the standardized *Ginkgo biloba* extract (EGb 761) are also given in Table 2.

3.2. Test on APP cleavage

Each extract was then tested at the highest not toxic concentration on CHO-APP cells during 16 h; the medium was then collected




Fig. 2. Measure of Aβ concentration in extracellular medium. (A) Aβ detected with 4G8 antibody. (B) Aβ detected with 6E10 antibody. CHO-APP cells were treated 16 h with DAPT (250 nM), *Pterocarpus erinaceus* aqueous extract (200 or 80 µg/ml) or *Ginkgo biloba* standardized extract (EGb761, 200 µg/ml); Aβ species were quantified in the extracellular medium using ECLIA method, and results were compared to media of non-treated cells (CTL). Each result was compared to control by a Student *t*-test; **p* < 0.05; ***p* < 0.01 (*n* = 3).

for Aβ quantification. Western-blot of cell-lysates were performed to analyze the amounts of cellular full-length APP (around 98 kDa) and of its C-terminal stubs (α-CTFs and β-CTFs, between 6 and 10 kDa). An increase of the CTF/APP ratio is generally considered as the hallmark of a decreased γ-cleavage of the CTFs, and thus an indicator of decreased γ-secretase activity in the cells (Kienlen-Campard et al., 2008).

Among all the tested extracts, *Pterocarpus erinaceus* aqueous extract gives the highest normalized CTF/APP ratio (5.2 ± 2.8 at 100 µg/ml); some other extracts as *Prosopis africana* EtOAc extract, *Trichilia emetica* hexanic extract and the cyclotide-enriched fraction of *Oldenlandia affinis*, give significantly high CTF/APP ratios, too.

Ginkgo biloba extract does not provide modifications vs. the control pattern. A very significant increase in CTF/APP ratio (see Fig. 1) was also observed as expected with DAPT (8.3 ± 3.9), a well-known γ-secretase inhibitor (Dovey et al., 2001).

3.3. Measure of produced Aβ for *Pterocarpus erinaceus*

Using ECLIA, we measured Aβ concentration in the extracellular medium of cells treated with *Pterocarpus erinaceus* aqueous extract, EGb761 or DAPT. We showed (Fig. 2) a significant decrease of Aβ38, Aβ40 and Aβ42, either using 4G8 or 6E10 antibodies, for *Pterocarpus erinaceus* extracts at 200 µg/ml. The decrease was also visible at 80 µg/ml, with values similar to those of DAPT at 250 nM. EGb761 did not decrease Aβ production, and even increased Aβ42 concentration.

4. Discussion

The cytotoxicity test on CHO cells showed that most hydrophobic extracts have some cytotoxicity, and that some of them, being clearly cytotoxic ($IC_{50} \leq 20$ µg/ml), may have some interest for the isolation of anticancer compounds or some risk of toxicity, especially *Cissampelos owariensis* CH₂Cl₂ extract, *Pterocarpus erinaceus* hexane and CH₂Cl₂ extracts. It is not the case for most water and EtOAc extracts, which may be considered as not toxic.

4.1. *Centella asiatica*

The Indian Pennywort (*Centella asiatica* (L.) Urban) is a small herbaceous plant of Indian origin, already known in Ayurvedic medicine, and widely used, especially in Asia and Madagascar, as vulnerary, vasoprotector, anti-ulcerous and pro-cognitive, effects

now mainly attributed to its triterpenes (Zheng and Qin, 2007). Recent studies of leaf extracts have shown not only *in vivo* spatial learning enhancement and memory retention, but also interesting tracks to an explanation of the traditional use as memory enhancer: extract given to 7-day old rat pups during 6 weeks increased the length and arborization of the dendrites of hippocampal (CA3 regions) neurons implicated in memorization (Mohandas Rao et al., 2006), and extract given *per os* to PS-APP mice (5 mg/kg/day during 8 months, beginning 2 months before the onset of amyloid plaques) diminishes Aβ in the hippocampus and fibrillar amyloid plaques in the cortex (Dhanasekaran et al., 2009).

In our results however, we obtained no significant effect on CTF/APP ratio, even with the methanolic extract. It should be noticed that the *in vivo* Aβ reduction mentioned by Dhanasekaran et al. (2009), took place after 8 months of treatment, and was not visible after 2 months; such treatment length is impossible in our screening test.

4.2. *Cissampelos owariensis* and *Heteranthera callifolia*

Mud-plantain (*Heteranthera callifolia* Rchb. ex Kunth), a small aquatic flower, and the twiner *Cissampelos owariensis* P. Beauvais ex D.C. are used together in decoction in Benin against dementia-type loss of memory. *Cissampelos owariensis* is also used in Benin against circulatory gynecological problems, against asthenia and (in association with *Rauwolfia vomitoria*) against madness (Adjanohoun et al., 1989). In the other African countries where *Cissampelos owariensis* is present, it is used for several purposes: against human and animal diarrhoea, to cure wounds or snake-bites, and, in Tanzania, against amnesia and psychoses (Schmelzer, 2008). No study has been made on these plants.

In our test, we did not observe any effect on APP processing for *Cissampelos owariensis* and *Heteranthera callifolia* extracts.

4.3. *Oldenlandia affinis*

Oldenlandia affinis (R. & S.) D.C. is used in Benin mixed in honey against learning retardation and in aqueous decoction as anticolic drink (Adjanohoun et al., 1989); it is also used in Centrafrican Republic and Congo D.R. (Zaire) as an ocytotic infusion (Gran et al., 2000). Interestingly, the plant was shown to contain, beside serotonin, several cyclotides, cyclic proteins of ab. 40 amino-acids, with three Cys–Cys bridges responsible for their special, compact structure, and first isolated from *Oldenlandia affinis*; cyclotides are

proteolysis-resistant, can cross the digestive barrier and have an oxytocin-like effect on uterine receptors (Gran et al., 2000). The interaction of cyclotides with β -amyloid peptide (which has the same length as cyclotides) has not been investigated.

In our study, cyclotide-enriched fraction of the MeOH-water maceration (but not the other extracts) raised significantly the CTF/APP ratio (2.1 ± 0.7).

4.4. *Parkia biglobosa*

Parkia biglobosa (Jacq.) R.Br. ex G. Don f. is an African tree; it is used in Benin against madness (twigs), against hypertension and hemorrhoids (bark), against abscesses (leaves), against snake-bites (also in Nigeria) (Adjahoun et al., 1989; Asuzu and Harvey, 2003); fruits are used as mosquito repellents in Guinea Bissau (Pålsson and Jaenson, 1999); fruit aqueous extract shows antidiabetic activity (Odetola et al., 2006).

Our results showed that EtOAc twig extract provided a slight but not significant increase in CTF/APP ratio (1.3 ± 0.3).

4.5. *Prosopis africana*

African Mesquite, *Prosopis africana* (Guill. & Perr.) Taub, is a tree used for different purposes in Benin. Leaved stem decoction is used against epilepsy, bark decoction against dermatose, and heart-wood decoction against learning retardation (Adjahoun et al., 1989). In other countries, the plant is also largely used against dermatoses and for anemia; leaves, roots and stems have been found to contain alkaloids (Kerharo and Adam, 1966; Khuong-Huu-Quy et al., 1972). This heart-wood, frequently used as *frotte-dents*, is imputrescible, maybe because of the antifungal and anti-insect activity of its extracts; the durability is due to its impenetrability by water: the wood cell lumen is filled by high-rated hydrophobic, non-extractible gums (Gerardin et al., 2004).

In our results, its EtOAc extract raised about twice CTF/APP ratio (2.2 ± 0.6).

4.6. *Pterocarpus erinaceus*

Barwood or African rosewood, *Pterocarpus erinaceus* Poiret, is a well-known workwood and dyestuff source; in Benin, the stem bark decoction is used against anaemia, dysmenorrhoea, dysentery and growth or learning retardation. It is also used in Senegal against dysentery and as breathing improver. The stem bark produces, spontaneously or after incision, a red exsudate, the kino of Gambia, which contains catechic tannins at 60% m/m (Kerharo and Adam, 1966; Adjahoun et al., 1989).

In our CHO-APP model, *Pterocarpus erinaceus* aqueous extract raised CTF/APP ratio (7.4 ± 3.2 at 200 μ g/ml, and 5.2 ± 2.8 at 100 μ g/ml). Like DAPT (which gives a 8.3 ± 3.9 CTF/APP ratio), it increases intensity of bands α - and β -CTF on cell-lysates Western-blot; however, unlike DAPT, it does not prevent AICD production (see Fig. 1), although it inhibits A β production as strongly as DAPT does at 250 nM (see Fig. 2). These observations joined together could be explained by the inhibition of γ -secretase activity at the γ -site (where A β is produced) without inhibition at the ε -site (where AICD is produced). Indeed, recent studies have shown that some compounds can inhibit one cleavage without inhibiting the other, and some mutations of APP have also an unequal effect on the two cleavages (Tolia and De Strooper, 2009). Such an effect on APP has the advantage not to decrease the production of AICD, which is involved in nuclear signaling and participates to APP physiological function by controlling gene transcription (Huyseune et al., 2009).

As this aqueous extract is rich in tannins, we also tested it after removal of polyphenols by retention on polyamide; this purified extract did show a reduced but still well significant increase in

CTF/APP ratio (2.1 ± 0.5 ; $p < 0.01$ vs. control cells as well as vs. crude aqueous extract). It indicates thus that tannins may play a role in the observed activity but are not the only effective compounds.

4.7. *Rauwolfia vomitoria*

Rauwolfia vomitoria Afzelius is a very well-known plant used in popular medicine in Benin, Ivory Coast and other African countries for several purposes, the main one being always madness (in decoction or brushed in a pasta); the used parts are roots (especially root bark) and, far less, leaves (Kerharo and Adam, 1966; Adjahoun et al., 1989). It is one of the richest plants in indolic alkaloids (dry roots contain 25% m/m), variously distributed in the organs of the plant, as for example reserpine (hypotensive, bradycardic and sedative) and ajmaline (Kerharo and Adam, 1966). We did not observe any increase in CTF/APP ratio with the leaves.

4.8. *Trichilia emetica* subsp. *suberosa*

Trichilia emetica Vahl. subsp. *suberosa* J.J.F.E. De Wilde has received its name from the strong emetic properties of its stem bark (which is also strongly cathartic); leaves are used as anthelmintic, vulnerary, against fever and against trypanosomias and malaria, to relieve rheumatismal pain or to treat convulsions or school retardation (Hoet, 2005); the roots contain phenolic acids (Germano et al., 2006), whereas leaves were studied for their polysaccharides (Diallo et al., 2003). In our study, hexanic extract of the leaves showed a significant increase of CTF/APP ratio (1.5 ± 0.4).

5. Conclusion

Our study presents elements indicating that some of these plants, used in Beninese and Malagasy traditional medicine to treat cognitive problems, contain compounds affecting the metabolism of APP, the precursor of A β peptide, the accumulation of which is characteristic of Alzheimer's disease. Especially, *Pterocarpus erinaceus* bark aqueous extract could be a promising object of study against Alzheimer's disease, due to the fact that it decreases β -amyloid peptide production; the next step will be the isolation and identification by bioguided fractionation of the constituents responsible for the observed *in vitro* activities.

Other extracts (*Prosopis africana* EtOAc and *Trichilia emetica* hexane, as well as *Oldenlandia affinis* cyclotide-enriched fraction) were also shown to significantly increase the CTF/APP ratio, an indicator of a possible inhibition of γ -secretase.

However, as this study provides only results obtained on cell cultures, we are aware that further studies should also be carried out in animals, to assess the activity but also the bioavailability of the isolated tested compounds or extracts, which is especially critical for an action in the central nervous system.

It must also be noted that the other extracts could be useful against memory problems, and even against Alzheimer's disease progression, without having shown any activity in our study. Their molecules could need a metabolic transformation before being active, or act upon other mechanisms implicated in Alzheimer's disease (for example, against amyloid aggregation, or against A β -induced neurotoxicity or oxidative stress). They could also act on dementia-related symptoms by enhancing cholinergic transmission like several Asian or European plants traditionally used for memory loss and now known for highly neuroprotective antioxidants and acetylcholine-esterase inhibitors (Perry et al., 1998; Howes and Houghton, 2003). Alzheimer's disease is also a very slow process, and effects may be only visible with long-term treatments, which are not possible on *in vitro* tests.

Finally, we found the *Pterocarpus erinaceus* aqueous extract to be a potent inhibitor of A β release in CHO cells expressing human

APP, and that this effect is still significant after removal of the tanins. This prompts us to further investigate precisely how the active compounds presents in the extract inhibit A β production in order to evaluate their therapeutic interest.

Acknowledgements

This work is supported by a grant of the Belgian F.R.I.A. (*Fonds pour la Formation à la Recherche dans l'Industrie et l'Agriculture*) (S.H.) and by the S.A.O./F.R.M.A. Foundation for Research on Alzheimer's Disease (P.K.-C.).

Pr. Didier M. Lambert (LDRI, U.C.L.) is gratefully acknowledged for the kind gift of CHO cells (ATCC, CCL-61), and for the continuous use of cell culture room. Dr. Willmar Schwabe (Karlsruhe, Germany) is acknowledged for the kind gift of EGb 761. We are also grateful to Mr. Pierre Agbani (botanist at the Abomay-Calavi University, Benin) and to the IMRA (Antananarivo, Madagascar) for plant collections and identifications, and to Pr. Giulio Muccioli (LDRI, U.C.L.) for useful discussion on cell cultures. We wish also to thank Mrs. Marie-Christine Fayt and Mrs. Bernadette Tasiaux, for their skillful technical assistance, and Miss Céline Rivière and Miss Laetitia Elhaylani for their practical help.

References

- Adjanohoun, E.J., Adjakidje, V., Ahyi, M.R.A., Aké assi, L., Akoegninou, A., d'Almeida, J., Apovo, F., Boukef, K., Chadare, M., Cusset, G., Dramane, K., Eyme, J., Gassita, J.-N., Gbaguidi, N., Goudote, E., Guinko, P., Houngnon, P., Lo, I., Keita, A., Kiniffo, H.V., Kone-Bamba, D., Musampa Nseyya, A., Saadou, M., Sodogandji, Th., de Souza, S., Tchabi, A., Zinsou Dossa, C., Zohoun, Th., 1989. Contribution aux études ethnobotaniques et floristiques en République Populaire du Bénin. Médecine traditionnelle et pharmacopée. Agence de Coopération culturelle et technique, Paris.
- Annaert, W., de Strooper, B., 2002. A cell biological perspective on Alzheimer's disease. Annual Review of Cell and Developmental Biology 18, 25–51.
- Asuzu, I.U., Harvey, A.L., 2003. The antsnake venom activities of *Parkia biglobosa* (Mimosaceae) stem bark extract. Toxicon 42, 763–768.
- Bastianetto, S., Ramassamy, C., Dore, S., Christen, Y., Poirier, J., Quirion, R., 2000. The *Ginkgo biloba* extract protects hippocampal neurones against cell death induced by beta-amyloid. European Journal of Neuroscience 12, 1882–1890.
- Best, J.D., Jay, M.T., Otu, F., Ma, J., Nadin, A., Ellis, S., Lewis, H.D., Pattison, C., Reilly, M., Harrison, T., Shearman, M.S., Williamson, T.L., Attack, J.R., 2005. Quantitative measurement of Changes in Amyloid-beta (40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575. The Journal of Pharmacology and Experimental Therapeutics 313, 902–908.
- Block, S., Stevigny, C., De Pauw-Gillet, M.-C., De Hoffmann, E., Llabres, G., Adjakidje, V., Quetin-Leclercq, J., 2002. Ent-trachyloban-3 β -ol, a new cytotoxic diterpene from *Croton zambesicus*. Planta Medica 68, 647–649.
- De Feudis, F.V., Drieu, K., 2000. *Ginkgo biloba* extract (EGb 761) and CNS functions: basic studies and clinical applications. Current Drug Targets 1, 25–58.
- Dhanasekaran, M., Holcomb, L.A., Hitt, A.R., Tharakan, B., Porter, J.W., Young, K.A., Manyam, B.V., 2009. *Centella asiatica* extract selectively decreases amyloid beta levels in hippocampus of Alzheimer's disease animal model. Phytotherapy Research: PTR 23, 14–19.
- Diallo, D., Paulsen, B.S., Liljeback, T.H.A., Michaelsen, T.E., 2003. The Malian medicinal plant *Trichilia emetica*; studies on polysaccharides with complement fixing ability. Journal of Ethnopharmacology 84, 279–287.
- Dovey, H.F., John, V., Anderson, J.P., Chen, L.Z., De Saint Andrieu, P., Fang, L.Y., Freedman, S.B., Folmer, B., Goldbach, E., Holsztyńska, E.J., Hu, K.L., Johnson-Wood, K.L., Kennedy, S.L., Kholodenko, D., Knops, J.E., Latimer, L.H., Lee, M., Liao, Z., Lieberburg, I.M., Motter, R.N., Mutter, L.C., Nietz, J., Quinn, K.P., Sacchi, K.L., Seubert, P.A., Shopp, G.M., Thorsett, E.D., Tung, J.S., Wu, J., Yang, S., Yin, C.T., Schenk, D.B., May, P.C., Alstiel, L.D., Bender, M.H., Boggs, L.N., Britton, T.C., Clemens, J.C., Czilli, D.L., Dieckman-McGinty, D.K., Droste, J.J., Fuson, K.S., Gitter, B.D., Hyslop, P.A., Johnstone, E.M., Li, W.-Y., Little, S.P., Mabry, T.E., Miller, F.D., Ni, B., Nissen, J.S., Porter, W.J., Potts, B.D., Reel, J.K., Stephenson, D., Su, Y., Shipley, L.A., Whitesitt, C.A., Yin, T., Audia, J.E., 2001. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. Journal of Neurochemistry 76, 173–181.
- Essalmani, R., Macq, A.-F., Mercken, L., Octave, J.-N., 1996. Missense mutations associated with familial Alzheimer's disease in Sweden lead to the production of the amyloid peptide without internalization of its precursor. Biochemical and Biophysical Research Communications 218, 89–96.
- European Pharmacopoeia, 2008, 6th ed. (<http://www.edqm.eu>).
- Gerardin, Ph., Neya, B., Dumarcay, St., Petrissans, M., Serraj, M., Huber, Fr., 2004. Contribution of gums to natural durability of *Prosopis africana* heartwood. Holz-forschung 58, 39–44.
- Germano, M.P., D'Angelo, V., Biasini, T., Sanogo, R., De Pasquale, R., Catania, S., 2006. Evaluation of the antioxidant properties and bioavailability of free and bound phenolic acids from *Trichilia emetica* Vahl. Journal of Ethnopharmacology 105, 368–373.
- Gran, L., Sandberg, F., Sletten, K., 2000. *Oldenlandia affinis* (R. & S.) DC. A plant containing uteroactive peptides used in African traditional medicine. Journal of Ethnopharmacology 70, 197–203.
- Herrmann, A., Burman, R., Mylne, J.S., Karlsson, G., Gullbo, J., Craik, D.J., Clark, R.J., Göransson, U., 2008. The alpine violet, *Viola biflora*, is a rich source of cyclotides with potent cytotoxicity. Phytochemistry 69, 939–952.
- Hoet, S., 2005. Ethnopharmacologically selected plants used to treat African trypanosomiasis: studies on their in vitro activity and chemical composition. PhD Thesis, U.C.L., Brussels.
- Houghton, P.J., Raman, A., 1998. A Laboratory Manual for the Fractionation of Natural Extracts. Chapman & Hall, London, p. 49.
- Howes, M.-J.R., Houghton, P.J., 2003. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacology Biochemistry and Behavior 75, 513–527.
- Huysseune, S., Kienlen-Campard, P., Octave, J.-N., 2007. Fe65 does not stabilize AICD during activation of transcription in a luciferase assay. Biochemical and Biophysical Research Communications 361, 317–322.
- Huysseune, S., Kienlen-Campard, P., Hebert, S., Tasiaux, B., Leroy, K., Devuyt, O., Brion, J.-P., De Strooper, B., Octave, J.-N., 2009. Epigenetic control of aquaporin 1 expression by the amyloid precursor protein. FASEB Journal 23, 4158–4167, FASEB=Federation of American Societies for Experimental Biology.
- Kerharo, J., Adam, J.G., 1966. La Pharmacopée Sénégalaise Traditionnelle. Vigot brothers, Paris.
- Khuong-Huu-Qui, Ratle, G., Monseur, X., Goutarel, R., 1972. Piperidine alkaloids. III. New alkaloids from *Prosopis africana*. Isoprosopinine A and B, prosophylline, prosafrine, and prosafrinine. Bulletin des Societes Chimiques Belges 81, 443–458.
- Kienlen-Campard, P., Octave, J.-N., 2002. Correlation between beta-amyloid peptide production and human APP-induced neuronal death. Peptides (New York, USA) 23, 1199–1204.
- Kienlen-Campard, P., Tasiaux, B., Van Hees, J., Li, M., Huysseune, S., Sato, T., Fei, J.Z., Aimoto, S., Courtoy, P.J., Smith, S.O., Constantinescu, S.N., Octave, J.-N., 2008. Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. Journal of Biological Chemistry 283, 7733–7744.
- Mohandas Rao, K.G., Muddanna Rao, S., Gurumadhva Rao, S., 2006. *Centella asiatica* (L.) leaf extract treatment during the growth spurt period enhances hippocampal CA3 neuronal dendritic arborization in rats. Evidence-based Complementary and Alternative Medicine 3, 349–357.
- Octave, J.-N., Essalmani, R., Tasiaux, B., Menager, J., Czech, C., Mercken, L., 2000. The role of presenilin-1 in the gamma-secretase cleavage of the amyloid precursor protein of Alzheimer's disease. The Journal of Biological Chemistry 275, 1525–1528.
- Odetola, A.A., Akinloye, O., Egunjobi, C., Adekunle, W.A., Ayoola, A.O., 2006. Possible antidiabetic and antihyperlipidaemic effect of fermented *Parkia biglobosa* (Jacq) Benth. extract in alloxan-induced diabetic rats. Clinical and Experimental Pharmacology and Physiology 33, 808–812.
- Pålsson, K., Jaenson, T.G., 1999. Plant products used as mosquito repellents in Guinea Bissau, West Africa. Acta Tropica 72, 39–52.
- Perry, E.K., Pickering, A.T., Wang, W.W., Houghton, P.J., Perry, N.S., 1998. Medicinal plants and Alzheimer's disease: integrating ethnobotanical and contemporary scientific evidence. Journal of Alternative and Complementary Medicine 4, 419–428.
- Schmelzer, G.H., 2008. Ressources végétales de l'Afrique tropicale 11(1). In: Plantes médicinales. PROTA, Wageningen, Netherlands.
- Suh, Y.H., Checler, F., 2002. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacological Reviews 54, 469–525.
- Tolia, A., De Strooper, B., 2009. Structure and function of γ -secretase. Seminars in Cell and Developmental Biology 20, 211–218.
- Wu, Y., Wu, Z., Butko, P., Christen, Y., Lambert, M.P., Klein, W.L., Link, C.D., Luo, Y., 2006. Amyloid-beta-induced pathological behaviors are suppressed by *Ginkgo biloba* extract EGb 761 and Ginkgolides in transgenic caenorhabditis elegans. The Journal of Neuroscience 26, 13102–13113.
- Yao, Z., Drieu, K., Papadopoulos, V., 2001. The *Ginkgo biloba* extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Research 889, 181–190.
- Zheng, C.-J., Qin, L.-p., 2007. Chemical components of *Centella asiatica* and their bioactivities. Journal of Chinese Integrative Medicine/Zhong Xi Yi Jie He Xue Bao 5, 348–351.